FDA Withdraws Emergency Use Authorization For AstraZeneca’s COVID-19 Antibody Cocktail Tixagevimab/Cilgavimab

Reuters (1/26) reports the FDA “has withdrawn emergency-use authorization for AstraZeneca’s COVID-19 antibody cocktail” tixagevimab/cilgavimab (Evusheld) “as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of Omicron.” The company “said it was informed that the agency will decide about reinstating authorization of Evusheld if the prevalence of resistant variants in the United States decreases to 90% or less on a sustained basis.”

Bloomberg Law (1/26, Subscription Publication) reports, “At this point, fewer than 10% of the variants currently circulating in the US appear to be responsive to Astra’s treatment…said” the agency in a statement.